potassium canrenoate Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
477 2181-04-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • potassium canrenoate
  • aldadiene kalium
  • aldadiene potassium
  • canrenoate potassium
  • canrenoate
  • kanrenol
  • canrenoic acid
  • canrenoic acid potassium
  • canrenoic acid potassium salt
A synthetic pregnadiene derivative with anti-aldosterone activity.
  • Molecular weight: 358.48
  • Formula: C22H30O4
  • CLOGP: 3.16
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 2
  • TPSA: 74.60
  • ALOGS: -3.91
  • ROTB: 3

Drug dosage:

DoseUnitRoute
0.40 g P

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sopor 131.01 33.29 46 2337 19782 46663897
Hyperkalaemia 122.46 33.29 57 2326 50652 46633027
Lactic acidosis 94.01 33.29 42 2341 33867 46649812
Hyponatraemia 80.72 33.29 55 2328 101277 46582402
Acute kidney injury 80.71 33.29 78 2305 235777 46447902
Drug interaction 80.69 33.29 73 2310 203021 46480658
Syncope 67.52 33.29 50 2333 104753 46578926
International normalised ratio increased 66.97 33.29 37 2346 46846 46636833
Toxic epidermal necrolysis 66.23 33.29 29 2354 22249 46661430
Asthenia 37.41 33.29 61 2322 311014 46372665
Hyponatraemic encephalopathy 36.93 33.29 7 2376 252 46683427
Hyponatraemic syndrome 36.67 33.29 8 2375 584 46683095
Hypoglycaemia 35.07 33.29 26 2357 54323 46629356
Dehydration 33.64 33.29 41 2342 159499 46524180

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperkalaemia 145.90 30.72 78 2089 65932 29884379
Hypotension 73.83 30.72 81 2086 200484 29749827
Melaena 73.27 30.72 39 2128 32398 29917913
Drug interaction 72.42 30.72 80 2087 199488 29750823
Sopor 65.61 30.72 26 2141 10965 29939346
Asthenia 64.04 30.72 79 2088 221211 29729100
Anaemia 50.27 30.72 68 2099 207924 29742387
Presyncope 49.96 30.72 24 2143 16032 29934279
Acute kidney injury 42.68 30.72 73 2094 273769 29676542
Hyponatraemia 39.16 30.72 35 2132 67167 29883144
Metabolic acidosis 35.62 30.72 26 2141 37435 29912876
Ascites 34.31 30.72 25 2142 35896 29914415
Oliguria 32.20 30.72 14 2153 7425 29942886

Pharmacologic Action:

SourceCodeDescription
ATC C03DA02 CARDIOVASCULAR SYSTEM
DIURETICS
POTASSIUM-SPARING AGENTS
Aldosterone antagonists
MeSH PA D004232 Diuretics
MeSH PA D006727 Hormone Antagonists
MeSH PA D000451 Mineralocorticoid Receptor Antagonists
MeSH PA D045283 Natriuretic Agents

Drug Use (View source of the data)

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.78 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D01943 KEGG_DRUG
4138-96-9 SECONDARY_CAS_RN
C0006881 UMLSCUI
CHEBI:50156 CHEBI
CHEMBL1616951 ChEMBL_ID
CHEMBL1371200 ChEMBL_ID
DB09015 DRUGBANK_ID
D002191 MESH_DESCRIPTOR_UI
23682215 PUBCHEM_CID
2448 INN_ID
2571 INN_ID
M671F9NLEA UNII
1981 RXNORM
003944 NDDF
003945 NDDF
318053000 SNOMEDCT_US
419615001 SNOMEDCT_US

Pharmaceutical products:

None